ACU301 / Acumen Pharma - LARVOL DELTA

EBD bispecific program (ACU301/ACU401) achieved up to ~40x higher brain exposure in NHPs and supports subcutaneous dosing (TradingView) - "IND targeted mid-2027."

IND • Preclinical • Alzheimer's Disease

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery (EBD) Development Candidates for the Treatment of Alzheimer’s Disease (The Manila Times) - "ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen’s option under its license agreement with JCR Pharmaceuticals...Acumen’s EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format; Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027."

IND • Pipeline update • Alzheimer's Disease

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights (The Manila Times) - "The Company currently expects to exercise its option to license two compounds developed as part of its collaboration with JCR Pharmaceuticals during the second quarter of 2026; The Company expects topline results from ALTITUDE-AD in late 2026....The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027."

IND • Licensing / partnership • P2 data • Alzheimer's Disease

Anticipated Milestones (The Manila Times) - "The Company expects topline results from ALTITUDE-AD, a Phase 2 study to investigate sabirnetug for the treatment of early Alzheimer’s disease, in late 2026; The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027."

IND • P2 data • Pipeline update • Alzheimer's Disease